FDA approves expanded use of AstraZeneca cancer drug

(Reuters) – The U.S. Food and Drug Administration said on Friday it has approved expanded use of AstraZeneca Plc’s cancer drug Lynparza to include patients with metastatic breast cancer whose disease is associated with a mutation of the BRCA gene.

Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *